Karoon’s balance sheet remains sound following the Who Dat acquisition. From a net cash position of USD 152 million or just over AUD 0.40 per share as of the end of September 2023, the balance sheet ...
We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...